Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD alpelisib - PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04589650 EPIK-P2 (CBYL719F12201) PIK3CA-related overgrowth spectrum Phase 2 150 Proportion of participants with a response at Week 24 Arm 1: alpelisib vs. Arm 2: placebo during the 16 first weeks, for each cohort (adult, pediatric), with placebo patients switching to alpelisib thereafter. Pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS) Primary Analysis: H1-2023 NA 105 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation